AIkido Pharma Inc. (NASDAQ:AIKI) Director Acquires $23,275.86 in Stock

AIkido Pharma Inc. (NASDAQ:AIKIGet Rating) Director Kyle Michael Wool acquired 3,559 shares of the stock in a transaction that occurred on Friday, September 16th. The shares were bought at an average price of $6.54 per share, for a total transaction of $23,275.86. Following the purchase, the director now directly owns 230,281 shares of the company’s stock, valued at $1,506,037.74. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

AIkido Pharma Stock Performance

AIkido Pharma stock opened at $6.88 on Thursday. The company has a 50 day moving average price of $6.10 and a 200 day moving average price of $6.10. The firm has a market capitalization of $36.10 million, a price-to-earnings ratio of -2.54 and a beta of 1.33. AIkido Pharma Inc. has a 52 week low of $4.30 and a 52 week high of $16.58.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AIkido Pharma stock. Equitec Proprietary Markets LLC acquired a new position in shares of AIkido Pharma Inc. (NASDAQ:AIKIGet Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 297,765 shares of the business services provider’s stock, valued at approximately $134,000. Equitec Proprietary Markets LLC owned 0.33% of AIkido Pharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 13.95% of the company’s stock.

About AIkido Pharma

(Get Rating)

AIkido Pharma Inc, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

Read More

Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with's FREE daily email newsletter.